Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target Raised to $195.00 at Royal Bank Of Canada

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price target boosted by analysts at Royal Bank Of Canada from $191.00 to $195.00 in a research report issued on Wednesday,Benzinga reports. The brokerage currently has an “outperform” rating on the specialty pharmaceutical company’s stock. Royal Bank Of Canada’s price target would suggest a potential upside of 1.17% from the stock’s previous close.

Other equities research analysts also recently issued reports about the company. Piper Sandler restated an “overweight” rating and set a $219.00 price objective (up from $147.00) on shares of Jazz Pharmaceuticals in a report on Wednesday, December 10th. Wall Street Zen upgraded shares of Jazz Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Needham & Company LLC upped their price target on shares of Jazz Pharmaceuticals from $210.00 to $235.00 and gave the company a “buy” rating in a report on Monday, January 12th. Truist Financial raised their price objective on shares of Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a “buy” rating in a report on Monday, January 12th. Finally, Wells Fargo & Company boosted their target price on shares of Jazz Pharmaceuticals from $235.00 to $250.00 and gave the stock an “overweight” rating in a research report on Wednesday. Fourteen research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Jazz Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $208.67.

Jazz Pharmaceuticals Stock Up 10.9%

Shares of Jazz Pharmaceuticals stock traded up $18.91 during trading hours on Wednesday, hitting $192.74. 2,054,267 shares of the company’s stock traded hands, compared to its average volume of 1,037,705. Jazz Pharmaceuticals has a twelve month low of $95.49 and a twelve month high of $194.83. The company has a market cap of $11.71 billion, a PE ratio of -31.78, a PEG ratio of 0.93 and a beta of 0.26. The company has a quick ratio of 1.44, a current ratio of 1.65 and a debt-to-equity ratio of 1.09. The stock has a 50 day simple moving average of $168.08 and a 200-day simple moving average of $150.27.

Insider Buying and Selling at Jazz Pharmaceuticals

In other news, SVP Mary Elizabeth Henderson sold 2,238 shares of the company’s stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $169.51, for a total value of $379,363.38. Following the completion of the sale, the senior vice president owned 19,508 shares in the company, valued at $3,306,801.08. This represents a 10.29% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CAO Patricia Carr sold 4,660 shares of the business’s stock in a transaction dated Friday, December 5th. The stock was sold at an average price of $171.20, for a total transaction of $797,792.00. Following the completion of the sale, the chief accounting officer owned 7,012 shares in the company, valued at approximately $1,200,454.40. This trade represents a 39.92% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 4.30% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. DGS Capital Management LLC acquired a new position in shares of Jazz Pharmaceuticals in the 4th quarter worth $260,000. Pacer Advisors Inc. lifted its stake in Jazz Pharmaceuticals by 19.8% during the fourth quarter. Pacer Advisors Inc. now owns 647,084 shares of the specialty pharmaceutical company’s stock valued at $110,004,000 after buying an additional 107,144 shares in the last quarter. Kera Capital Partners Inc. acquired a new stake in Jazz Pharmaceuticals during the 4th quarter worth about $336,000. Dean Capital Management grew its holdings in shares of Jazz Pharmaceuticals by 3.2% during the 4th quarter. Dean Capital Management now owns 21,158 shares of the specialty pharmaceutical company’s stock valued at $3,597,000 after acquiring an additional 654 shares in the last quarter. Finally, Compound Planning Inc. acquired a new position in Jazz Pharmaceuticals during the fourth quarter worth $313,000. Institutional investors own 89.14% of the company’s stock.

Key Stories Impacting Jazz Pharmaceuticals

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Q4 beat — Jazz reported Q4 revenue of $1.20B and EPS of $6.64, both topping Street estimates, and closed 2025 with record total revenues of $4.3B. Press Release
• Positive Sentiment: Product momentum — Management highlighted strong commercial performance: Xywav reached $1.7B (+12% YoY), Epidiolex $1.1B (+9% YoY) and Modeyso delivered $37M in its first full quarter, supporting top-line growth. Product Highlights
• Positive Sentiment: 2026 revenue guide — Jazz issued 2026 total revenue guidance of $4.25B–$4.50B and management reiterated progress on rare-disease and oncology launches (including an expected sBLA RTOR filing for zanidatamab). This outlook is a near-term catalyst. Revenue Outlook
• Positive Sentiment: Analyst upgrade — Bank of America raised its price target to $275 and reiterated a Buy rating, signaling significant analyst upside versus current levels and likely supporting investor demand. Benzinga
• Neutral Sentiment: Investor materials posted — The full earnings call transcript and the Q4 slide deck are available for review (useful for modeling product/launch assumptions and margin drivers). Earnings Transcript Presentation
• Neutral Sentiment: Street analysis — Coverage pieces (Zacks, Seeking Alpha previews) compare metrics to estimates and highlight what to watch (oncology launches, sBLA timing) — useful but not new surprises. Zacks Analysis
• Negative Sentiment: Margin and profitability notes — Despite the beat, some filings/coverage flag a negative net margin (reported -8.86% in the quarter) and other accounting/expense dynamics that could pressure reported profitability or require clarification from management. MarketBeat Earnings Summary

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.